85. Idiopathic interstitial pneumonia Clinical trials / Disease details

Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-002632-24-FR (EUCTR)	13/11/2018	20/07/2018	to evaluate a triple therapy: plasma exchange, rituximab, intravenous immunoglobulin (IVIg) and corticosteroid administration compared to standard corticosteroid therapy in patients for severe acute exacerbation of idiopathic pulmonary	Therapeutic plasma exchange, rituximab and intravenous immunoglobulins (IVIg) for severe acute exacerbation of idiopathic pulmonary fibrosis admitted in ICU: an open, randomized, controlled trial - EXCHANGE-IFP	severe acute exacerbation of idiopathic pulmonary fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: RIXATHON 500 mg Trade Name: PRIVIGEN 100mg/ml	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	France
2	NCT03286556 (ClinicalTrials.gov)	September 4, 2018	12/9/2017	Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis	Study of Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF)	Idiopathic Pulmonary Fibrosis, Acute Fatal Form	Drug: Autoantibody Reductive Therapy;Drug: Treatment as Usual (TAU)	University of Alabama at Birmingham	National Heart, Lung, and Blood Institute (NHLBI);Brigham and Women's Hospital;Temple University;University of Pittsburgh	Recruiting	40 Years	85 Years	All	51	Phase 2	United States
3	NCT03500731 (ClinicalTrials.gov)	April 19, 2018	30/3/2018	Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure	Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure	Idiopathic Pulmonary Fibrosis;Emphysema or COPD	Biological: CD3/CD19 negative hematopoietic stem cells;Drug: Rituximab;Drug: Alemtuzumab;Drug: Fludarabine;Drug: Thiotepa;Drug: G-CSF;Drug: Hydroxyurea	Paul Szabolcs	NULL	Recruiting	18 Years	60 Years	All	8	Phase 1/Phase 2	United States
4	NCT01969409 (ClinicalTrials.gov)	January 2014	17/10/2013	Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis	Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis (ART-IPF)	Ambulatory IPF	Drug: Rituximab;Drug: Placebo	University of Alabama at Birmingham	National Institutes of Health (NIH)	Completed	50 Years	85 Years	All	58	Phase 2	United States
5	NCT01524068 (ClinicalTrials.gov)	September 2012	27/1/2012	A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations	A Multicenter, Open-Label, Phase II Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis Exacerbations	Idiopathic Pulmonary Fibrosis	Drug: Standard Steroid Treatment;Drug: The Standard Steroid Treatment, Plasma Exchange and rituximab	University of Pittsburgh	NULL	Withdrawn	18 Years	90 Years	Both	0	Phase 2	United States
6	NCT01266317 (ClinicalTrials.gov)	March 2011	22/12/2010	Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations	Open-Label, Feasibility Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis Exacerbations	IPF	Drug: Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids	Michael Donahoe	NULL	Completed	18 Years	80 Years	All	9	Phase 1/Phase 2	United States